세계의 표준 펜니들 시장 : 시장 규모, 점유율, 성장 및 산업 분석 - 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of standard pen needles Market

The global standard pen needles market is witnessing steady growth driven by the rising prevalence of diabetes, increasing adoption of insulin pens, and ongoing technological innovations in needle design. According to the latest market assessment, the market was valued at USD 1.56 billion in 2024, projected to grow to USD 1.65 billion in 2025, and is expected to reach USD 2.62 billion by 2032, reflecting a CAGR of 6.8% over the forecast period. North America dominated the market in 2024, holding a 38.46% share, supported by advanced healthcare infrastructure, widespread awareness, and strong adoption of home-based diabetes management solutions.

Standard pen needles are single-use medical devices used for subcutaneous delivery of insulin and other injectable medications via insulin pens. They are available in various gauges and lengths, designed to enhance precision, comfort, and convenience, particularly for self-administration. The market's growth is primarily fueled by the global surge in diabetes cases, rising preference for insulin pens over traditional syringes, and the adoption of ultra-fine and shorter needle designs that improve patient compliance, especially among needle-phobic users.

Market Drivers

The primary growth driver is the rising global prevalence of diabetes. Factors such as sedentary lifestyles, aging populations, increasing obesity rates, and poor dietary habits have contributed to a surge in diabetes diagnoses worldwide. According to the International Diabetes Federation, over 530 million adults were living with diabetes in 2023, with numbers expected to increase significantly in the coming decades. The widespread use of insulin therapy, particularly for Type 1 and advanced Type 2 diabetes, has amplified the demand for compatible pen needles.

The increasing adoption of insulin pens is another key driver. Insulin pens offer ease of use, portability, and accurate dosing, making them the preferred choice over traditional syringes. Educational campaigns and government initiatives aimed at improving diabetes awareness and access to insulin delivery devices further strengthen market growth. For instance, in August 2024, Breakthrough T1D launched the national campaign "Detect so you can decide," promoting early detection and insulin usage.

Market Restraints

The market faces certain constraints due to needle phobia, poor injection compliance, and lack of adherence to guidelines. Approximately 28% of diabetic patients worldwide experience anxiety or fear related to needle-based injections, potentially reducing adherence to prescribed insulin regimens. Reuse of pen needles, particularly in developing regions, further limits market expansion. In addition, inconsistent reimbursement policies and limited awareness in some regions hamper widespread adoption.

Market Opportunities

Expanding the market in middle-income countries offers significant opportunities. Regions in Asia, Latin America, and Africa are experiencing rapid increases in diabetes prevalence. Companies like Novo Nordisk are actively supplying insulin pens at reduced prices in countries like South Africa, promoting affordability and accessibility. Governments and NGOs focusing on non-communicable diseases present additional growth opportunities through local partnerships, product customization, and distribution networks.

Market Trends

Technological innovations are reshaping the market. Manufacturers are developing ultra-fine, thin-gauge needles with shorter lengths and advanced lubrication coatings to reduce pain and improve adherence. Safety-engineered mechanisms, including retractable needles and shielded designs, minimize needlestick injury risks. Integration with digital smart pens allows real-time insulin dose tracking, enhancing patient compliance and enabling remote disease management.

Segmentation Analysis

• By Drug Type: The insulin segment dominates due to long-term and widespread use, while GLP-1 therapies are projected to grow as new treatments for obesity and diabetes are approved.
• By Disease Indication: Diabetes leads due to the large patient base requiring chronic injectable therapies, whereas obesity shows promising growth as more patients adopt subcutaneous treatment regimens.
• By Needle Size: The 4 mm needle dominates for comfort and reduced intramuscular injection risk. 6 mm needles are growing for adults with higher BMI or obesity treatment.
• By Distribution Channel: Retail pharmacies account for the largest share, offering convenience and accessibility, while online pharmacies are expected to grow fastest, supported by e-commerce and telehealth expansion.

Regional Outlook

• North America dominated with USD 0.60 billion in 2024, benefiting from advanced healthcare infrastructure, home-based diabetes monitoring, and favorable reimbursement policies.
• Europe holds a significant share due to robust healthcare systems and high awareness of self-injection therapies.
• Asia Pacific is projected to witness the highest CAGR, fueled by increasing diabetes prevalence in China and India, growing health awareness, and improved healthcare access.
• Latin America and Middle East & Africa are growing steadily, driven by government initiatives, rising chronic disease awareness, and expanding healthcare infrastructure.

Competitive Landscape

The market is fragmented, with major players including Embecta Corp., BD, Cardinal Health, Terumo Corporation, and Owen Mumford. Companies focus on new product launches, strategic partnerships, and geographical expansion to maintain market share. Notable developments include Braun SE's 2025 collaboration with Orlando Health to develop innovative solutions improving patient access to insulin delivery devices.

In conclusion, the standard pen needles market is set to grow from USD 1.56 billion in 2024 to USD 2.62 billion by 2032, driven by rising diabetes prevalence, adoption of insulin pens, and technological advancements. With increased home-based care, patient-friendly needle designs, and expanding market access in emerging regions, the industry is poised for sustainable growth worldwide.

Segmentation By Drug Type, Disease Indication, Needle Size, Distribution Channel, and Region

By Drug Type * Insulin

• GLP-1
• Growth Hormone
• Others

By Disease Indication * Diabetes

• Obesity
• Hormone Deficiency
• Others

By Needle Size * 4 mm

• 5 mm
• 6 mm
• 8 mm
• 12 mm

By Distribution Channel * Hospital Pharmacy

• Retail Pharmacy
• Online Pharmacy

By Region * North America (By Drug Type, Disease Indication, Needle Size, Distribution Channel, and Country)

U.S.

Canada

• Europe (By Drug Type, Disease Indication, Needle Size, Distribution Channel, and Country/Sub-region)

Germany

U.K.

France

Spain

Italy

Rest of Europe

• Asia Pacific (By Drug Type, Disease Indication, Needle Size, Distribution Channel, and Country/Sub-region)

China

Japan

India

Australia

Rest of Asia Pacific

• Latin America (By Drug Type, Disease Indication, Needle Size, Distribution Channel, and Country/Sub-region)

Brazil

Mexico

Rest of Latin America

• Middle East & Africa (By Drug Type, Disease Indication, Needle Size, Distribution Channel, and Country/Sub-region)

GCC

South Africa

Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. New Product Launches, By Key Players
• 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
• 4.3. Technological Advancements in Biopharmaceutical Processing

5. Global Standard Pen Needles Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Drug Type
  • 5.1.1. Insulin
  • 5.1.2. GLP-1
  • 5.1.3. Growth Hormone
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.2.1. Diabetes
  • 5.2.2. Obesity
  • 5.2.3. Hormone Deficiency
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Needle Size
  • 5.3.1. 4 mm
  • 5.3.2. 5 mm
  • 5.3.3. 6 mm
  • 5.3.4. 8 mm
  • 5.3.5. 12 mm
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacy
  • 5.4.2. Retail Pharmacy
  • 5.4.3. Online Pharmacy
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Standard Pen Needles Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Drug Type
  • 6.1.1. Insulin
  • 6.1.2. GLP-1
  • 6.1.3. Growth Hormone
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.2.1. Diabetes
  • 6.2.2. Obesity
  • 6.2.3. Hormone Deficiency
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Needle Size
  • 6.3.1. 4 mm
  • 6.3.2. 5 mm
  • 6.3.3. 6 mm
  • 6.3.4. 8 mm
  • 6.3.5. 12 mm
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacy
  • 6.4.2. Retail Pharmacy
  • 6.4.3. Online Pharmacy
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Standard Pen Needles Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Drug Type
  • 7.1.1. Insulin
  • 7.1.2. GLP-1
  • 7.1.3. Growth Hormone
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.2.1. Diabetes
  • 7.2.2. Obesity
  • 7.2.3. Hormone Deficiency
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Needle Size
  • 7.3.1. 4 mm
  • 7.3.2. 5 mm
  • 7.3.3. 6 mm
  • 7.3.4. 8 mm
  • 7.3.5. 12 mm
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacy
  • 7.4.2. Retail Pharmacy
  • 7.4.3. Online Pharmacy
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia pacific Standard Pen Needles Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Drug Type
  • 8.1.1. Insulin
  • 8.1.2. GLP-1
  • 8.1.3. Growth Hormone
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.2.1. Diabetes
  • 8.2.2. Obesity
  • 8.2.3. Hormone Deficiency
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Needle Size
  • 8.3.1. 4 mm
  • 8.3.2. 5 mm
  • 8.3.3. 6 mm
  • 8.3.4. 8 mm
  • 8.3.5. 12 mm
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacy
  • 8.4.2. Retail Pharmacy
  • 8.4.3. Online Pharmacy
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Standard Pen Needles Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Drug Type
  • 9.1.1. Insulin
  • 9.1.2. GLP-1
  • 9.1.3. Growth Hormone
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.2.1. Diabetes
  • 9.2.2. Obesity
  • 9.2.3. Hormone Deficiency
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Needle Size
  • 9.3.1. 4 mm
  • 9.3.2. 5 mm
  • 9.3.3. 6 mm
  • 9.3.4. 8 mm
  • 9.3.5. 12 mm
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacy
  • 9.4.2. Retail Pharmacy
  • 9.4.3. Online Pharmacy
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Standard Pen Needles Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Drug Type
  • 10.1.1. Insulin
  • 10.1.2. GLP-1
  • 10.1.3. Growth Hormone
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.2.1. Diabetes
  • 10.2.2. Obesity
  • 10.2.3. Hormone Deficiency
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Needle Size
  • 10.3.1. 4 mm
  • 10.3.2. 5 mm
  • 10.3.3. 6 mm
  • 10.3.4. 8 mm
  • 10.3.5. 12 mm
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacy
  • 10.4.2. Retail Pharmacy
  • 10.4.3. Online Pharmacy
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
  • 11.2.1. Embecta Corp.
  • 11.2.2. Cardinal Health
  • 11.2.3. MTD Medical Technology and Devices
  • 11.2.4. UltiMed, Inc.
  • 11.2.5. Allison Medical, Inc.
  • 11.2.6. Owen Mumford
  • 11.2.7. Medline Industries, LP
  • 11.2.8. B. Braun SE
  • 11.2.9. Neon Diagnostics Limited
  • 11.2.10. Other Prominent Players